Q3 2020 Sales Performance

PRIMA: Comparing PARPI and bevacizumab in 1L ovarian cancer gsk N PRIMA1 niraparib SOLO-12 olaparib PAOLA-13 bevacizumab VELIA4 veliparib GOG-2185 bevacizumab ICON 76 bevacizumab +/- olaparib 733 391 806 1140 1873 1528 Overall 0.62 0.59 0.68 0.73 0.87 population HR deficient BRCAmut 0.40 0.30 0.31 0.44 ND (-20% of patients*) 0.95 HR deficient BRCAwt 0.50 0.43 0.74 NS ND (-30% of patients*) HR proficient BRCAwt 0.68 0.92 NS 0.81 NS 0.71 ND (~50% of patients*) Only Zejula demonstrated efficacy in all patient HR subgroups in first line (1) Gonzalez, ESMO 2019; (2) MORE, NEJM 2018; (3) Ray-Coquard ESMO 2019; Coleman ESMO 2019; (5) Burger NEJM 2011; (6) Perren NEJM 2011 * Patients with known BRCA and HR status 49 49

View entire presentation